News

AstraZeneca to Harness Benefits of Genome-Editing Technology

By Marta Falconi (The Wall Street Journal) – ZURICH—British drug maker AstraZeneca PLC unveiled agreements on Thursday that should enable the pharmaceutical company to tap into a promising, nascent gene technology aimed at making drugs more precise.

Read More

Obama’s Precision Medicine Initiative: Paying For Precision Drugs Is The Challenge

By David Kroll (Forbes) – Earlier this afternoon, I had read that in tonight’s State of the Union address, President Obama was to discuss the fruits of the Human Genome Project in the context of what’s become known as precision medicine.

Read More

Meet the 2012 and 2014 Damon Runyon-Sohn Fellows

Each fall, the Damon Runyon Cancer Research Foundation holds their annual retreat where their Fellows come together for scientific exchange and collegiality.  We are pleased to share videos of the 2012 and 2014 classes of Damon Runyon-Sohn Fellows.

Read More

End of Cancer-Genome Project Prompts Rethink of Research Strategy

By Heidi Ledford (Scientific American) – A mammoth US effort to genetically profile 10,000 tumours has officially come to an end. Started in 2006 as a US$100-million pilot, The Cancer Genome Atlas (TCGA) is now the biggest component of the International Cancer Genome Consortium, a collaboration of scientists from 16 nations that has discovered nearly … Continued

Read More

Pershing Square Sohn Cancer Research Alliance Attends the 5th Annual Galien Forum

The Pershing Square Sohn Cancer Research Alliance recently sponsored a panel entitled, “Pioneers for a Cure: the Role of Innovation and Entrepreneurship in Cancer Research” at the 5th Annual Galien Forum.

Read More

On Cancer: Study Reveals How Some Breast Cancers Become Resistant to Targeted Drugs

By Julie Grisham, MS, Science Writer/Editor  |  Monday, November 17, 2014 – For people with advanced breast cancer, several clinical trials have shown that experimental targeted drugs called PI3K inhibitors can temporarily halt the spread of disease. But eventually the tumors learn to outwit the drugs and begin growing again.

Read More

Google’s Newest Search: Cancer Cells

By Alistair Barr and Ron Winslow (The Wall Street Journal) – Google Inc. is designing tiny magnetic particles to patrol the human body for signs of cancer and other diseases, in the latest example of the Internet giant’s sweeping ambition.

Read More

PRESS RELEASE: Applications Open for the 2015 Pershing Square Sohn Prize for Young Investigators in Cancer Research

New York, October 2, 2014– The Pershing Square Sohn Cancer Research Alliance (PSSCRA) today announced the opening of applications for its Prize for Young Investigators in Cancer Research. The prize of $200,000 per year for up to three years is awarded annually to five New York City-based scientists, enabling them to pursue cutting-edge research at … Continued

Read More

Young, Brilliant and Underfunded

By Andy Harris (The New York Times) WASHINGTON — EVERY year the National Institutes of Health receives almost $30 billion in federal funds to invest in biomedical research. The bulk of that money goes to researchers who are in many cases esteemed in their fields — but also, in many cases, beyond the age when … Continued

Read More

A NOTCH1-driven MYC enhancer promotes T cell development, transformation and acute lymphoblastic leukemia

Abstract: Efforts to identify and annotate cancer driver genetic lesions have been focused primarily on the analysis of protein-coding genes; however, most genetic abnormalities found in human cancer are located in intergenic regions.

Read More